IP Library Granted Patent US 11,351,256
Granted Patent B2
US 11,351,256 · App. 15/727,457 · Granted Jun 7, 2022

Room temperature stable lyophilized protein

Inventors: Xiaolin Tang (Old Tappan, NJ); David Brett Ludwig (New York, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A61K39/39591A61J1/1412A61K9/0019A61K9/08A61K9/19A61K47/02A61K47/10A61K47/183A61K47/26A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,351,256
App. No.
15/727,457
Granted
Jun 7, 2022
Kind
B2
Abstract

Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. Also, the inclusion of a multicomponent stabilizer comprising a larger molecular entity and a smaller molecular entity is described. Also, the inclusion of post-drying annealing under certain conditions improves protein stability. Proteins are predicted to remain stable over 24 months at 25° C.

Claims (41)

1. A lyophilized cake comprising:

(a) a protein;

(b) a stabilizer, wherein said stabilizer comprises about 5% sucrose by weight in the pre-lyophilized formulation and arginine in a weight to weight ratio of sucrose to arginine from about 3.2:1 to about 3.4:1;

(c) a buffer; and

(d) a moisture content of from about 3% to about 6% by weight,

wherein the lyophilized cake is not collapsed.

2. The lyophilized cake of claim 1 , wherein said lyophilized cake:

(i) comprises no yellow, no brown, no black, and no red color;

(ii) is not melted and comprises no density variation; and/or

(iii) comprises a glass transition temperature above 25° C.

3. The lyophilized cake of claim 1 , comprising a moisture content of from about 3.5% to about 5.5% by weight.

4. The lyophilized cake of claim 3 , comprising a moisture content of about 4.5% by weight.

5. The lyophilized cake of claim 1 , wherein said buffer comprises histidine at about 0.34% to about 2.04% by weight.

6. The lyophilized cake of claim 1 , wherein said stabilizer is:

(a) selected from the group consisting of a polyol, a sugar, an amino acid, a salt, and combinations thereof, wherein (i) said polyol is selected from the group consisting of sorbitol, glycerol, mannitol, and a combination thereof; (ii) said sugar is selected from the group consisting of trehalose, sucrose, and a combination thereof; (iii) said amino acid is selected from the group consisting of arginine, alanine, proline, glycine, and a combination thereof; and (iv) said salt is sodium chloride; and/or

(b) present at about 19% to about 83% by weight.

7. The lyophilized cake of claim 1 , wherein said stabilizer further comprises mannitol, wherein said mannitol is present at about 8% to about 23% by weight.

8. The lyophilized cake of claim 1 , wherein said stabilizer further comprises sorbitol, wherein said sorbitol is present at about 1.3% to about 23% sorbitol by weight.

9. The lyophilized cake of claim 1 further comprising a surfactant, wherein:

(a) said surfactant is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyethylene glycol (PEG), PEG 3350, and a combination thereof; or

(b) said surfactant is present at about 0.02% to about 1% by weight.

10. The lyophilized cake of claim 1 , wherein said protein is present from about 6% to about 64% by weight.

11. The lyophilized cake of claim 1 , wherein said protein is selected from the group consisting of an antigen-binding protein, an antibody, an antibody fragment, and a receptor-Fc-fusion protein.

12. The lyophilized cake of claim 1 , wherein said lyophilized cake is contained within a vial, wherein said vial comprises type I borosilicate glass and is closed with a polytetrafluorethylene coated butyl rubber stopper.

13. A lyophilized cake comprising:

(a) a protein;

(b) a stabilizer at a ratio of about 0.2 parts stabilizer to 1 part protein by weight (0.2:1) to about 1.5 parts stabilizer to 1 part protein by weight (1.5:1), wherein said stabilizer comprises arginine, sorbitol, glycerol and/or alanine; and

(c) a moisture content of from about 3% to about 6% by weight,

wherein said lyophilized cake is free of discoloration.

14. The lyophilized cake of claim 13 , wherein the ratio of the stabilizer to protein by weight is between about 0.22:1 and about 1.3:1 by weight.

15. The lyophilized cake of claim 13 , wherein said stabilizer:

(a) is selected from the group consisting of a non-reducing sugar, a sugar alcohol, an amino acid, and a combination thereof, wherein said non-reducing sugar comprises sucrose or trehalose; said sugar alcohol is selected from the group consisting of sorbitol, mannitol, and glycerol; and said amino acid is selected from the group consisting of arginine, alanine, proline, and glycine; or

(b) comprises sucrose or trehalose.

16. The lyophilized cake of claim 15 (b) further comprising arginine, mannitol or sorbitol, wherein:

(a) the ratio of sucrose to arginine is about 3.2:1 to about 3.4:1 by weight;

(b) the ratio of sucrose to mannitol is about 1.8:1 to about 2:1 by weight;

(c) the ratio of trehalose to arginine is about 3.2:1 to about 3.4:1 by weight; or

(d) the ratio of trehalose to sorbitol is about 1:1 to about 2:1 by weight.

17. The lyophilized cake of claim 13 , wherein said protein is selected from the group consisting of an antibody, an antibody fragment, and a receptor-Fc-fusion protein.

18. The lyophilized cake of claim 13 , further comprising a buffer, wherein said buffer is selected from the group consisting of citrate, phosphate, histidine, succinate, carbonate, acetate, and a combination thereof.

19. The lyophilized cake of claim 13 , wherein said lyophilized cake is contained within a vial or a syringe.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: TANG, XIAOLIN; LUDWIG, DAVID BRETT
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 044594/0015 →
Continuity (2)
Provisional Application 62405610 · Oct 7, 2016
Related Publication 20180099049A1 · Apr 12, 2018
Cited By (2)
US 12,449,198 US 12,514,925